NeuClone gibt präklinische Ergebnisse von Biosimilar-Kandidaten für Stelara® (Ustekinumab) bekannt
NeuClone announced positive preclinical results for its Stelara® biosimilar, confirming structural integrity via X-ray crystallography. Developed with Serum Institute of India, it's set for Phase I trials in 2019. Stelara®, a monoclonal antibody, treats diseases like plaque psoriasis and Crohn's disease. NeuClone focuses on biosimilar development using its NeuMAX® platform.
Reference News
NeuClone announced positive preclinical results for its Stelara® biosimilar, confirming structural integrity via X-ray crystallography. Developed with Serum Institute of India, it's set for Phase I trials in 2019. Stelara®, a monoclonal antibody, treats diseases like plaque psoriasis and Crohn's disease. NeuClone focuses on biosimilar development using its NeuMAX® platform.